SYNEXUS CLINICAL RESEARCH LIMITED
Company Information
- Company Number
- 05575991
- Registered Address
- 12b Granta Park Great Abington, Cambridge, England, CB21 6GQ
- Status
- Active
- Employee Count
- 18.0
- Turnover
- 76426000.0
- EBITDA
- -8951000.0
Additional Details
- Website
- https://radiantresearch.com/
- Company Type
- Private limited Company
- Incorporated On
- 27 September 2005
- Nature of Business
- 74909 - Other professional, scientific and technical activities not elsewhere classified
- Industries
- Life Sciences And Medical Technology
- Region
- East of England
Company Location
Financial Metrics
Time to Pay
Payment Timeline
Payment Features
Payment Time Trends
Payment Distribution Trends
Performance Reports History
| Reporting Period | Filing Date | Average Time to Pay (days) | Paid within 30 days | Paid 31-60 days | Paid after 60 days | Not Paid within Terms |
|---|---|---|---|---|---|---|
| 01 Jul 2023 - 31 Dec 2023 | 31 Jan 2024 | 52 | 46% | 36% | 18% | 79% |
| 01 Jan 2023 - 30 Jun 2023 | 01 Aug 2023 | 36 | 41% | 49% | 10% | 87% |
| 01 Jul 2022 - 31 Dec 2022 | 30 Jan 2023 | 47 | 31% | 45% | 24% | 84% |
| 01 Jan 2022 - 30 Jun 2022 | 18 Jul 2022 | 36 | 39% | 47% | 14% | 75% |
| 01 Jul 2021 - 31 Dec 2021 | 31 Jan 2022 | 30 | 68% | 23% | 9% | 42% |
| 01 Jan 2021 - 30 Jun 2021 | 22 Jul 2021 | 29 | 70% | 26% | 4% | 46% |
| 01 Jul 2020 - 31 Dec 2020 | 22 Jan 2021 | 28 | 80% | 17% | 3% | 25% |
| 01 Jan 2020 - 30 Jun 2020 | 23 Jul 2020 | 31 | 72% | 23% | 5% | 41% |
| 01 Jul 2019 - 31 Dec 2019 | 27 Jan 2020 | 31 | 71% | 24% | 5% | 43% |
| 01 Jan 2019 - 30 Jun 2019 | 05 Aug 2019 | 42 | 31% | 55% | 14% | 84% |
| 01 Jul 2018 - 31 Dec 2018 | 31 Jan 2019 | 39 | 26% | 63% | 11% | 58% |
| 01 Jan 2018 - 30 Jun 2018 | 10 Aug 2018 | 49 | 47% | 31% | 22% | 56% |
Company Summary
Synexus Clinical Research Limited is a leading global clinical research organization that provides innovative solutions for drug development
The company was founded in 1992 and is headquartered in Manchester, UK
The company's activities include conducting clinical trials for pharmaceutical and biotechnology companies, as well as providing research services for medical device and diagnostic companies
They have a global network of research centers in Europe, Africa, and the Americas, enabling them to offer a wide range of study locations and patient populations
Synexus is committed to sustainability and has implemented various initiatives to reduce their environmental impact
They have a sustainability program in place that focuses on reducing energy consumption, waste, and carbon emissions
The company also encourages and supports eco-friendly practices among their employees and partners
The company's products and services include patient recruitment, site management, data management, and safety monitoring
They also offer specialized services such as biospecimen management and medical imaging
Synexus has a team of experienced researchers and clinicians who work closely with their clients to ensure the success of their clinical trials
Key people at Synexus include CEO Dr
Christophe Berthoux and Executive Chairman Dr
Mike Laska
The company's website address is www.synexus.com, where interested parties can find more information about their services, ongoing studies, and career opportunities
The registered office address is 1 Rivergate, Temple Quay, Bristol, BS1 6ED, UK
In summary, Synexus Clinical Research Limited is a trusted and reliable partner for pharmaceutical and biotechnology companies, providing high-quality clinical research services
Their commitment to sustainability, wide range of products and services, and experienced team make them a leader in the field of clinical research
Company Review
Trend Analysis
The data shows a general trend of improvement in the average time taken for SYNEXUS CLINICAL RESEARCH LIMITED to pay invoices to suppliers. From 2018 to 2023, there is a consistent decrease in the average time to pay, with the lowest being 28 days in 2020. This suggests that the company is becoming more efficient in paying its invoices.
Volatility Analysis
There is some volatility in the percentage of invoices paid within 30 days, with a high of 80% in 2021 and a low of 26% in 2018. However, overall there is a steady increase in the percentage of invoices paid within 30 days, which indicates an improvement in the company's payment processes.
Summary Analysis
Looking at the last three periods (2021-2023), there is a slight increase in the average time taken to pay invoices, from 29 days in 2021 to 52 days in 2023. However, the percentage of invoices paid within 30 days remains relatively stable at around 70%, with a slight decrease in 2023. There is also an increase in the percentage of invoices paid later than 60 days, from 9% in 2021 to 18% in 2023. This could indicate a potential issue with payment delays in the future.
Invoice Payment Practices
This information is as reported by the business, and responses are in their own words.
Payment Terms
Standard payment terms
60 Days
Were there any changes to the standard payment terms in the reporting period?
No
Any other information about payment terms
N/A
Maximum contractual payment period agreed
60
Dispute Resolution Process
Synexus has a dedicated email address (apglobalaes.sm@ppd.com) where support is offered to vendors in the event of disputes or queries on invoice payment. The email address is checked regularly by the accounting team and all queries are resolved immediately.
Other Payment Information
Has this business signed up to a code of conduct or standards on payment practices?
For example, signatories to The Prompt Payment Code must commit to paying 95% of their invoices within 60 days.
❌
Does this business offer e-invoicing in relation to qualifying contracts?
This is where suppliers can electronically submit and track invoices. It's not just allowing suppliers to email them an invoice.
❌
Does this business offer supply chain finance?
This is where a supplier who has submitted an invoice can be paid by a third-party finance provider earlier than the agreed payment date. The business would then pay the finance provider the invoiced sum.
❌
Under its payment practices and policies, can this business deduct sums from payments under qualifying contracts as a charge for remaining on a supplier list?
❌
During the reporting period, did the business deduct sums from payments as a charge for remaining on a supplier list?
No information available